<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568265</url>
  </required_header>
  <id_info>
    <org_study_id>APG1387BC201</org_study_id>
    <nct_id>NCT04568265</nct_id>
  </id_info>
  <brief_title>A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, open-label, phase II clinical study in subjects with chronic&#xD;
      hepatitis B (CHB), to characterize the safety, tolerability, pharmacokinetic profile and&#xD;
      preliminary anti-hepatitis B virus (HBV) efficacy of APG-1387 in combination with entecavir,&#xD;
      and to determine the optimal dose of APG-1387 in combination with entecavir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into two parts:&#xD;
&#xD;
      Part 1 will evaluate the safety, tolerability, and pharmacokinetics of APG-1387 in&#xD;
      combination with entecavir, including determination of the maximum tolerated dose (MTD)/&#xD;
      recommended dose in patients with CHB. APG-1387 will be administered once weekly via&#xD;
      intravenous infusion for 30 minutes for consecutive 4 weeks. APG-1387 will be escalated at 3&#xD;
      dose cohorts of 12 mg, 20 mg, and 30 mg. Entecavir will be administered orally at 0.5 mg&#xD;
      daily for 12 weeks: in combination with APG-1387 for the first 4 weeks, followed by entecavir&#xD;
      maintenance monotherapy for additional 8 weeks. The total treatment duration will be 12&#xD;
      weeks.&#xD;
&#xD;
      Part 2 is a randomized, parallel, open-label study to investigate the preliminary anti-HBV&#xD;
      efficacy of APG-1387 in combination with entecavir compared with entecavir monotherapy. CHB&#xD;
      subjects will be randomly assigned to one of 4 cohorts at 1:1:1:1, including APG-1387 at 3&#xD;
      different doses (12 mg, 20 mg, and 30 mg) in combination with entecavir for 12 weeks,&#xD;
      respectively, then continued entecavir monotherapy for additional 12 weeks; and one entecavir&#xD;
      monotherapy cohort for 24 weeks. The course of treatment is 24 weeks in all cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) rate at each dose level</measure>
    <time_frame>28 days</time_frame>
    <description>DLT will be assessed within the first 28-day cycle of study treatment via NCI CTCAE version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decline in Hepatitis B surface Antigen (HBsAg)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The difference in HBsAg decline between APG-1387 combined with entecavir arms and entecavir monotherapy arm</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Chronic Hep B</condition>
  <condition>HBV</condition>
  <arm_group>
    <arm_group_label>APG-1387 12 mg combined with entecavir 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>APG-1387 20 mg combined with entecavir 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>APG-1387 30 mg combined with entecavir 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>entecavir 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG-1387</intervention_name>
    <description>Weekly intravenous infusion for 30 minutes</description>
    <arm_group_label>APG-1387 12 mg combined with entecavir 0.5 mg</arm_group_label>
    <arm_group_label>APG-1387 20 mg combined with entecavir 0.5 mg</arm_group_label>
    <arm_group_label>APG-1387 30 mg combined with entecavir 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir 0.5 mg</intervention_name>
    <description>Taken daily by mouth</description>
    <arm_group_label>APG-1387 12 mg combined with entecavir 0.5 mg</arm_group_label>
    <arm_group_label>APG-1387 20 mg combined with entecavir 0.5 mg</arm_group_label>
    <arm_group_label>APG-1387 30 mg combined with entecavir 0.5 mg</arm_group_label>
    <arm_group_label>entecavir 0.5 mg</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) within the range of 18 - 27.9&#xD;
&#xD;
          -  Documented chronic HBV infection (e.g., HBsAg positive for at least 6 months).&#xD;
&#xD;
          -  HBeAg-positive or HBeAg-negative&#xD;
&#xD;
          -  Treatment-naïve and treatment-experienced subjects are required to:&#xD;
&#xD;
               1. Treatment-naïve subjects:&#xD;
&#xD;
                    -  No antiviral therapies including nucleos(t)ide analogues or immunomodulators&#xD;
                       such as interferon within 180 days prior to screening&#xD;
&#xD;
                    -  HBV DNA ≥ 2x10˄3 IU/mL for HBeAg negative subjects and ≥ 2x10˄4 IU/mL for&#xD;
                       HBeAg positive subjects (PCR)&#xD;
&#xD;
                    -  Alanine transaminase (ALT) ≥ upper limit of normal (ULN) and &lt; 10 × ULN (and&#xD;
                       excluding ALT elevation caused by non-HBV reasons such as drug or alcohol&#xD;
                       consumption)&#xD;
&#xD;
               2. Treatment-experienced subjects:&#xD;
&#xD;
                    -  Using entecavir &gt; 180 days prior to screening, and should continue the&#xD;
                       treatment regimen until enrolled into the study&#xD;
&#xD;
                    -  HBV DNA less than the lower limit of quantification (LLOQ) or &lt; 20 IU/mL&#xD;
                       (PCR)&#xD;
&#xD;
                    -  ALT &lt; 1.5 × ULN&#xD;
&#xD;
          -  Adequate hematological function:&#xD;
&#xD;
               -  White blood cell count (WBC) ≥ 3.5 × 10˄9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 120 g/L for males and ≥ 110 g/L for females&#xD;
&#xD;
               -  Platelet count ≥ 100 × 10˄9/L&#xD;
&#xD;
          -  Adequate renal and liver function:&#xD;
&#xD;
               -  Serum creatinine ≤ 1×ULN&#xD;
&#xD;
               -  Serum albumin ≥ 35.0g/L&#xD;
&#xD;
               -  Urine protein is negative or 1 + (re-examination is required when 1 + or 24-hour&#xD;
                  urine protein quantification is added when necessary. If it turns negative or is&#xD;
                  within the normal range, it can be included)&#xD;
&#xD;
               -  Estimated creatinine clearance (CLCr) ≥ 50 mL/min based on serum creatinine&#xD;
                  measured at the screening assessment and actual body weight (calculated&#xD;
                  creatinine clearance by the Cockcroft-Gault formula)&#xD;
&#xD;
               -  Total bilirubin ≤1.5×ULN&#xD;
&#xD;
               -  International normalized ratio (INR) ≤ 1.5×ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5×ULN&#xD;
&#xD;
          -  Female subjects of childbearing potential should have a negative serum pregnancy test&#xD;
             within 7 days prior to the first dose&#xD;
&#xD;
          -  Subjects and theirs partners are willing to use effective contraception as defined in&#xD;
             the protocol during the treatment and for at least 6 months after the last dose of&#xD;
             study drug&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent form (the&#xD;
             consent form must be signed by the subject prior to any study-specific procedures)&#xD;
&#xD;
          -  Willingness and ability to comply with study procedures and follow-up examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-infection with HIV, hepatitis C virus (HCV), or hepatitis delta virus (HDV); or&#xD;
             other active and severe infections&#xD;
&#xD;
          -  Syphilis with positive antibody for treponema pallidum&#xD;
&#xD;
          -  Subjects with liver disease other than hepatitis B, including but not limited to&#xD;
             chronic alcoholic hepatitis, drug-induced liver injury, autoimmune liver disease,&#xD;
             hereditary liver disease (such as Wilson's disease), and active hepatitis due to other&#xD;
             causes&#xD;
&#xD;
          -  History or manifestation of hepatic decompensation (e.g., Child-Pugh Class B or C, or&#xD;
             history of ascites, gastrointestinal bleeding, hepatic encephalopathy, or spontaneous&#xD;
             bacterial peritonitis)&#xD;
&#xD;
          -  Progressive fibrosis/cirrhosis, defined by liver fibrosis scan ≥ 12 kilopascal (kPa)&#xD;
             at screening, or cirrhosis diagnosed by imaging examinations, or Metavir score F3, F4&#xD;
             fibrosis on liver biopsy at any time&#xD;
&#xD;
          -  Clinically diagnosed hepatocellular carcinoma, or diagnosis of hepatocellular&#xD;
             carcinoma cannot be excluded, or serum alpha-fetoprotein greater than 50 μg/L&#xD;
&#xD;
          -  History of malignancy (except cured and no evidence of recurrence of basal cell&#xD;
             carcinoma of the skin or situ cervical cancer) or lymphoproliferative disease&#xD;
&#xD;
          -  History of neurological or mental disorders, such as epilepsy, dementia, and poor&#xD;
             compliance&#xD;
&#xD;
          -  Uncontrolled primary diseases of other important organs, such as clear medical history&#xD;
             of nervous system, cardiovascular system, urinary system (including chronic or&#xD;
             intermittent urinary system diseases), digestive system, respiratory system,&#xD;
             endocrine/metabolic and musculoskeletal system, such as poorly controlled diabetes,&#xD;
             hypertension, etc., making the investigator consider the subject unsuitable&#xD;
&#xD;
          -  QTcB [QTcB = QT/(RR^ 0.5); RR is the normalized heart rate value, obtained by dividing&#xD;
             60 by heart rate in seconds; other parameters in milliseconds] &gt; 450 milliseconds for&#xD;
             men and &gt; 470 milliseconds for women; any clinically important abnormality in the&#xD;
             rhythm, conduction, or morphology of the resting electrocardiogram (ECG) (e.g.,&#xD;
             complete left bundle branch block, third degree heart block, second degree heart&#xD;
             block); congenital long QT syndrome or family history of long QT syndrome&#xD;
&#xD;
          -  History of alcoholism (mean daily intake of ethanol ≥ 30 g (male) or ≥ 20 g (female)&#xD;
             within 1 year), and drug abuse&#xD;
&#xD;
          -  Subjects planning to become pregnant within 1 year, who are pregnant or breastfeeding&#xD;
&#xD;
          -  Received or may receive continuous treatment with immunomodulators (e.g., steroids) or&#xD;
             biological agents (e.g., monoclonal antibodies, interferons) within 3 months before&#xD;
             screening&#xD;
&#xD;
          -  Participated in clinical trials within 3 months before screening&#xD;
&#xD;
          -  Trauma or major surgical operation within 4 weeks before screening&#xD;
&#xD;
          -  Previous treatment with inhibitors of apoptosis proteins&#xD;
&#xD;
          -  Any subject considered unsuitable for the trial by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifan Zhai, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ascentage Pharma Group Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujuan Guan, Master</last_name>
      <phone>+86-020-83710459</phone>
      <email>gz8hgyj@126.com</email>
    </contact>
    <investigator>
      <last_name>Yujuan Guan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinlin Hou, Master</last_name>
      <phone>+86-020-62787427</phone>
      <email>jlhousmu@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinlin Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jimin Zhang, Doctor</last_name>
      <phone>+86-021-52888262</phone>
      <email>jmzhang@vip.126.com</email>
    </contact>
    <investigator>
      <last_name>Jimin Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enqiang Chen, Doctor</last_name>
      <phone>+86-028-8542 3052</phone>
      <email>chenenqiang1983@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Enqiang Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBeAg-positive</keyword>
  <keyword>HBeAg-negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

